Schizophrenia epidemiology and demographics

Jump to navigation Jump to search

Schizophrenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Schizophrenia from other Disorders

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Psychotherapy

Brain Stimulation Therapy

Social Impact

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Schizophrenia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Schizophrenia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Schizophrenia epidemiology and demographics

CDC on Schizophrenia epidemiology and demographics

Schizophrenia epidemiology and demographics in the news

Blogs on Schizophrenia epidemiology and demographics

Directions to Hospitals Treating Schizophrenia

Risk calculators and risk factors for Schizophrenia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Epidemiology

Schizophrenia occurs equally in males and females although typically appears earlier in men with the peak ages of onset being 20–28 years for males and 26–32 years for females. Much rarer are instances of childhood-onset[1] and late- (middle age) or very-late-onset (old age) schizophrenia.[2] The lifetime prevalence of schizophrenia, that is, the proportion of individuals expected to experience the disease at any time in their lives, is commonly given at 1%. A 2002 systematic review of many studies, however, found a lifetime prevalence of 0.55%. Despite the received wisdom that schizophrenia occurs at similar rates throughout the world, its prevalence varies across the world,[3] within countries,[4] and at the local and neighbourhood level.[5] One particularly stable and replicable finding has been the association between living in an urban environment and schizophrenia diagnosis, even after factors such as drug use, ethnic group and size of social group have been controlled for.[6] Schizophrenia is known to be a major cause of disability. In a 1999 study of 14 countries, active psychosis was ranked the third-most-disabling condition, after quadriplegia and dementia and before paraplegia and blindness.[7]

References

  1. Kumra S, Shaw M, Merka P, Nakayama E, Augustin R. (2001) Childhood-onset schizophrenia: research update. Canadian Journal of Psychiatry, 46 (10), 923–30.
  2. Hassett A, Ames D, Chiu E (eds) (2005) Psychosis in the Elderly. London: Taylor and Francis. ISBN 18418439446
  3. Jablensky A, Sartorius N, Ernberg G, et al. (1992) Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine Monograph Supplement, 20, 1–97. PMID 1565705
  4. Kirkbride JB, Fearon P, Morgan C, et al. (2006) Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings From the 3-center ÆSOP study. Archives of General Psychiatry, 63, 250–258. PMID 16520429
  5. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Murray RM, Jones PB. (2007) Neighbourhood variation in the incidence of psychotic disorders in Southeast London. Social Psychiatry and Psychiatric Epidemiology, 42(6), 438-45. PMID 17473901
  6. Van Os J. (2004). Does the urban environment cause psychosis? British Journal of Psychiatry, 184 (4), 287–288. PMID 15056569
  7. Ustun TB, Rehm J, Chatterji S, Saxena S, Trotter R, Room R, Bickenbach J, and the WHO/NIH Joint Project CAR Study Group (1999). Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. The Lancet, 354(9173), 111–115. PMID 10408486

Template:WH Template:WS